EMPOWER-Lung 3 is a placebo-controlled, phase 3 study, which examined the efficacy and safety of Cemiplimab plus platinum-doublet chemotherapy in previously untreated NSCLC patients, irrespective of PD-L1 expression or histology [47]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.